Tag: obesity drug

Eli Lilly has advanced its novel non-incretin obesity drug into Phase 3 clinical trials after promising Phase 2 results. This move marks a significant milestone in the evolving obesity-treatment landscape, as the company explores mechanisms beyond the incretin pathway. The announcement highlights the growing diversification of obesity therapies and intensifying competition among global pharma leaders.